Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: povidone; iron oxide red; crospovidone; hypromellose phthalate; hyprolose; macrogol 400; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; microcrystalline cellulose; macrogol 6000; pregelatinised maize starch; glyceryl monostearate; polysorbate 80; light magnesium oxide; silicon dioxide; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: purified talc; silicon dioxide; microcrystalline cellulose; povidone; pregelatinised maize starch; macrogol 6000; hyprolose; crospovidone; iron oxide red; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; hypromellose phthalate; macrogol 400; polysorbate 80; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - jubium is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: macrogol 400; glyceryl monostearate; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); silicon dioxide; purified talc; light magnesium oxide; povidone; polysorbate 80; hyprolose; iron oxide red; hypromellose phthalate; crospovidone; pregelatinised maize starch; macrogol 6000; titanium dioxide; hypromellose; maize starch; sucrose - jubeso is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; microcrystalline cellulose; silicon dioxide; iron oxide red; purified talc; hyprolose; macrogol 400; pregelatinised maize starch; macrogol 6000; light magnesium oxide; polysorbate 80; hypromellose phthalate; povidone; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - jubeso is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: iron oxide red; glyceryl monostearate; macrogol 400; silicon dioxide; polysorbate 80; povidone; light magnesium oxide; hypromellose phthalate; microcrystalline cellulose; macrogol 6000; purified talc; crospovidone; pregelatinised maize starch; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - jubium is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: light magnesium oxide; pregelatinised maize starch; glyceryl monostearate; macrogol 6000; hypromellose phthalate; crospovidone; silicon dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide red; macrogol 400; polysorbate 80; microcrystalline cellulose; povidone; purified talc; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; microcrystalline cellulose; povidone; silicon dioxide; macrogol 400; macrogol 6000; hyprolose; pregelatinised maize starch; hypromellose phthalate; iron oxide red; crospovidone; purified talc; light magnesium oxide; polysorbate 80; titanium dioxide; hypromellose; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: silicon dioxide; hyprolose; iron oxide red; macrogol 6000; glyceryl monostearate; hypromellose phthalate; purified talc; povidone; crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; polysorbate 80; pregelatinised maize starch; macrogol 400; microcrystalline cellulose; titanium dioxide; hypromellose; maize starch; sucrose - jubeso is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: silicon dioxide; crospovidone; macrogol 400; polysorbate 80; povidone; purified talc; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide red; microcrystalline cellulose; pregelatinised maize starch; macrogol 6000; light magnesium oxide; hyprolose; hypromellose phthalate; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - jubeso is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Israel - English - Ministry of Health

taro international ltd, israel - esomeprazole - tablets - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophgeal reflux disease (gerd)in combination with antibiotics in treatment of duodenal ulcer caused by helicobactor pylori